Acrivon Therapeutics
Cambridge
About Acrivon Therapeutics
Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success. They specifically apply its approach to challenging oncology drug targets causally implicated in the vast majority of cancers, particularly those without simple single-gene driver mutations or synthetic lethal contexts. The company aims to rapidly progress in-licensed clinical-stage assets and a pipeline of internally developed programs through accelerated registration trials.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $245.5M
- Funding stage: IPO
- Last round: Post-IPO Equity (Apr 2024)
- Ticker: nasdaq:ACRV
- Website: acrivon.com
- Phone: +1 617 207-8979
Industries & Categories
Biotechnology, Health Care, Oncology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/acrivon-therapeutics-59441 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.